Skip to main content

Table 2 Comparison between cirrhotic and non-cirrhotic patients regarding baseline patients’ age, biochemical parameters, and Framingham risk score

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Baseline parameter Cirrhotic patients (n = 22) Non-cirrhotic patients (n = 68) Student’s t-test
t p
Age (years) 51.045 ± 10.781 45.529 ± 10.267 2.164 0.033
AST (IU/l) 55.955 ± 35.77 45.971 ± 24.985 1.457 0.149
ALT (IU/l) 70.909 ± 50.675 48.824 ± 33.663 2.344 0.021
Albumin (g/dl) 3.653 ± 0.487 4.05 ± 0.393 −3.881 <0.001
Total bilirubin (mg/dl) 0.94 ± 0.524 0.698 ± 0.308 2.663 0.009
Direct bilirubin (mg/dl) 0.464 ± 0.233 0.349 ± 0.234 2.012 0.047
INR 1.165 ± 0.156 1.087 ± 0.114 2.546 0.013
Hemoglobin (g/dl) 13.136 ± 1.593 13.557 ± 1.548 −1.101 0.274
Total leucocyte count (103/μl) 5.695 ± 1.861 7.150 ± 2.487 −2.520 0.014
Platelet count (103/μl) 159.727 ± 71.748 219.044 ± 80.611 −3.077 0.003
LDL (mg/dl) 39.001 ± 7.528 80.397 ± 19.489 −9.701 <0.001
Total cholesterol (mg/dl) 122.409 ± 29.156 182.103 ± 33.774 −7.436 <0.001
HDL (mg/dl) 40.136 ± 5.375 50.544 ± 5.462 −7.798 <0.001
Lp-PLA2 (ng/ml) 335.455 ± 74.345 320.941 ± 82.023 0.737 0.463
Framingham risk score 10.323 ± 9.921 8.175 ± 8.205 1.013 0.314
  1. Abbreviations: n, number; AST, aspartate transaminase; ALT, alanine transaminase; INR, international normalized ratio; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2